GlassScriptPhysician profile
Thomas L Cao
NPI 1194797266
$4,056.34
in general payments reported to CMS, 2019-2025
34 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $494 · 2021: $279 · 2022: $618 · 2023: $751 · 2024: $715 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.74 |
| Education | $107.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $683.57 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $565.10 | 2019-2024 | Eliquis, Opdualag |
| Janssen Biotech, INC. | $382.07 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $346.84 | 2019-2024 | Enhertu, Imfinzi, Lynparza |
| Lilly USA, LLC | $308.13 | 2019-2024 | Jaypirca, Verzenio |
| Incyte Corporation | $244.24 | 2019-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $227.46 | 2020-2025 | |
| Genentech USA, INC. | $121.25 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $111.99 | 2019-2022 | |
| Seagen INC. | $96.03 | 2020-2023 | Tukysa |
| Taiho Oncology, INC. | $94.09 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $88.61 | 2022-2024 | Keytruda, Lynparza |
| Emd Serono, INC. | $82.74 | 2019-2020 | |
| Daiichi Sankyo INC. | $78.07 | 2019-2023 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $68.25 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $66.42 | 2019-2020 | |
| Celgene Corporation | $63.84 | 2019-2024 | Reblozyl |
| Alnylam Pharmaceuticals INC. | $54.58 | 2020-2023 | Givlaari |
| Abbvie INC. | $44.94 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.25 | 2020-2024 | |
| Pharmacosmos Therapeutics INC. | $30.98 | 2022 | |
| Amgen INC. | $30.74 | 2019-2020 | |
| Genzyme Corporation | $27.23 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $26.38 | 2019 | |
| Amag Pharmaceuticals, INC. | $25.15 | 2021 | |
| Tesaro, INC. | $24.31 | 2019 | |
| Blue Earth Diagnostics | $22.44 | 2021 | |
| Fortovia Therapeutics, INC. | $18.93 | 2019 | |
| Kite Pharma, INC. | $17.77 | 2020 | |
| Beigene USA, INC. | $15.11 | 2024 | Brukinsa |
| Eisai INC. | $14.97 | 2020 | |
| Rigel Pharmaceuticals, INC. | $14.51 | 2019 | |
| Mylan Institutional INC. | $12.43 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.